Self-control Trial to Evaluate the Remission Rate in Newly Diagnosed Type 2 Diabetes Patients After Treatment With Insulin Aspart

Self-control Trial to Evaluate the Remission Rate and Safety in Newly Diagnosed Type 2 Diabetes Patients After Short-term Intensive Insulin Aspart and Insulin NPH Treatment

Status

Completed

Phases

Phase 4

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT00494988

Enrollment

Registered

2007-07-02

Start date

2004-12-31

Completion date

2006-04-30

Last updated

2016-03-04

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Diabetes, Diabetes Mellitus, Type 2

Brief summary

This trial is conducted in Asia. The aim of this trial is evaluate the remission rate in newly diagnosed subjects with type 2 diabetes after short-term intensive treatment with insulin aspart and insulin NPH.

Interventions

DRUGinsulin aspart

DRUGinsulin NPH

Study design

Allocation

NON_RANDOMIZED

Intervention model

SINGLE_GROUP

Primary purpose

TREATMENT

Masking

NONE

Eligibility

Sex/Gender

ALL

Age

18 Years to 50 Years

Healthy volunteers

Inclusion criteria

* Type 2 diabetes newly diagnosed within 6-12 months * FBG: 11.1-17.0 mmol/L * Body mass index (BMI) larger than 25.0 kg/m2

Exclusion criteria

* Known or suspected allergy to trial product(s) or related products * Recurrent major hypoglycaemia as judged by the Investigator

Design outcomes

Primary

Measure	Time frame
Remission rate	after 24 weeks

Secondary

Measure	Time frame
blood glucose profiles	—
HbA1c	—

Countries

China

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026